Association between a frequent allele of the gene encoding OATP1B1 and enhanced LDL-lowering response to fluvastatin therapy

Pharmacogenomics

Volumn 9, Issue 9, 2008, Pages 1217-1227

  Couvert, Philippe ^a,b   Giral, Philippe ^a,b   Dejager, Sylvie ^c   Gu, Jessie ^d   Huby, Thierry ^a,b   Chapman, M John ^a,b   Bruckert, Eric ^a,b   Carrie, Alain ^a,b  

^a PITIÉ SALPÊTRIÈRE HOSPITAL   (France)

^b SORBONNE UNIVERSITÉ   (France)

^c NOVARTIS PHARMA K K   (Japan)

^d NOVARTIS INSTITUTES FOR BIOMEDICAL RESEARCH   (United States)

Author keywords

Hypercholesterolemia; Hypolipidemic response; Pharmacogenetic

Indexed keywords

ALANINE; ASPARAGINE; ASPARTIC ACID; CHOLESTEROL; FLUINDOSTATIN; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; LESCOL XL; LIPID; LOW DENSITY LIPOPROTEIN CHOLESTEROL; ORGANIC ANION TRANSPORTER 2; PLACEBO; PROLINE; THREONINE; TRIACYLGLYCEROL; UNCLASSIFIED DRUG; VALINE;

AGED; ALLELE; ARTICLE; CARDIOVASCULAR RISK; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG MECHANISM; DRUG RESPONSE; FEMALE; GENE FREQUENCY; GENE LINKAGE DISEQUILIBRIUM; GENETIC ASSOCIATION; GENETIC VARIABILITY; GENOTYPE; HETEROZYGOSITY; HOMOZYGOSITY; HUMAN; HYPERCHOLESTEROLEMIA; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; RANDOMIZED CONTROLLED TRIAL; RISK REDUCTION; SINGLE NUCLEOTIDE POLYMORPHISM; SUSTAINED RELEASE FORMULATION; TREATMENT OUTCOME; WILD TYPE;

AGED; AGED, 80 AND OVER; ALLELES; ANTICHOLESTEREMIC AGENTS; CHOLESTEROL, LDL; DOUBLE-BLIND METHOD; FATTY ACIDS, MONOUNSATURATED; FEMALE; HUMANS; HYPERCHOLESTEROLEMIA; INDOLES; LINKAGE (GENETICS); MALE; ORGANIC ANION TRANSPORTERS;

EID: 55449085527     PISSN: 14622416     EISSN: 17448042     Source Type: Journal    
DOI: 10.2217/14622416.9.9.1217     Document Type: Article

References (43)

1. Baigent C, Keech A, Kearney PM et al.: Efficacy and safety of cholesterol-lowering treatment: prospective meta-analysis of data from 90,056 participants in 14 randomised trials of statins. Lancet 366, 1267-1278 (2005).
2. Cannon CP, Braunwald E, McCabe CH et al.: Intensive versus moderate lipid lowering with statins after acute coronary syndromes. N. Engl. J. Med. 350, 1495-1504 (2004).
3. de Lemos JA, Blazing MA, Wiviott SD et al.: Early intensive vs a delayed conservative simvastatin strategy in patients with acute coronary syndromes: phase Z of the A to Z trial. JAMA 292, 1307-1316 (2004).
4. LaRosa JC, Grundy SM, Waters DD et al.: Intensive lipid lowering with atorvastatin in patients with stable coronary disease. N. Engl. J. Med. 352, 1425-1435 (2005).
5. Pedersen TR, Faergeman O, Kastelein JJ et al.: High-dose atorvastatin vs usual-dose simvastatin for secondary prevention after myocardial infarction: the IDEAL study: a randomized controlled trial. JAMA 294, 2437-2445 (2005).
6. Jacobson TA: Statin safety: lessons from new drug applications for marketed statins. Am. J. Cardiol. 97,C44-C51 (2006).
7. Silva M, Matthews ML, Jarvis C et al.: Meta-analysis of drug-induced adverse events associated with intensive-dose statin therapy. Clin. Ther. 29, 253-260 (2007).
8. Mukhtar RY, Reckless JP: Statin-induced myositis: a commonly encountered or rare side effect? Curr. Opin. Lipidol. 16, 640-647 (2005).
9. Schuetz EG, Schinkel AH: Drug disposition as determined by the interplay between drug-transporting and drug-metabolizing systems. J. Biochem. Mol. Toxicol. 13, 219-222 (1999).
10. Hsiang B, Zhu Y, Wang Z et al.: A novel human hepatic organic anion transporting polypeptide (OATP2). Identification of a liver-specific human organic anion transporting polypeptide and identification of rat and human hydroxymethylglutaryl-CoA reductase inhibitor transporters. J. Biol. Chem. 274, 37161-37168 (1999).
11. Nezasa K, Higaki K, Takeuchi M, Nakano M, Koike M: Uptake of rosuvastatin by isolated rat hepatocytes: comparison with pravastatin. Xenobiotica 33, 379-388 (2003).
12. Hirano M, Maeda K, Shitara Y, Sugiyama Y: Contribution of OATP2 (OATP1B1) and OATP8 (OATP1B3) to the hepatic uptake of pitavastatin in humans. J. Pharmacol. Exp. Ther. 311, 139-146 (2004).
13. Kopplow K, Letschert K, Konig J, Walter B, Keppler D: Human hepatobiliary transport of organic anions analyzed by quadruple-transfected cells. Mol. Pharmacol. 68, 1031-1038 (2005).
14. Ho RH, Tirona RG, Leake BF et al.: Drug and bile acid transporters in rosuvastatin hepatic uptake: function, expression, and pharmacogenetics. Gastroenterology 130, 1793-1806 (2006).
15. Sai Y, Tsuji A: Transporter-mediated drug delivery: recent progress and experimental approaches. Drug Discov. Today 9, 712-720 (2004).
16. Hagenbuch B, Meier PJ: The superfamily of organic anion transporting polypeptides. Biochim. Biophys. Acta 1609, 1-18 (2003).
17. Niemi M: Role of OATP transporters in the disposition of drugs. Pharmacogenomics 8, 787-802 (2007).
18. Sabia H, Prasad P, Smith HT, Stoltz RR, Rothenberg P: Safety, tolerability, and pharmacokinetics of an extended-release formulation of fluvastatin administered once daily to patients with primary hypercholesterolemia. J. Cardiovasc. Pharmacol. 37, 502-511 (2001).
19. Noe J, Portmann R, Brun ME, Funk C: Substrate-dependent drug-drug interactions between gemfibrozil, fluvastatin and other organic anion-transporting peptide (OATP) substrates on OATP1B1, OATP2B1, and OATP1B3. Drug Metab. Dispos. 35, 1308-1314 (2007).
20. Abe T, Kakyo M, Tokui T et al.: Identification of a novel gene family encoding human liver-specific organic anion transporter LST-1. J. Biol. Chem. 274, 17159-17163 (1999).
21. Tirona RG, Leake BF, Merino G, Kim RB: Polymorphisms in OATP-C: identification of multiple allelic variants associated with altered transport activity among European- and African-Americans. J. Biol. Chem. 276, 35669-35675 (2001).
22. Tirona RG, Kim RB: Pharmacogenomics of organic anion-transporting polypeptides (OATP). Adv. Drug Deliv. Rev. 54, 1343-1352 (2002).
23. Nozawa T, Nakajima M, Tamai I et al.: Genetic polymorphisms of human organic anion transporters OATP-C (SLC21A6) and OATP-B ( SLC21A9): allele frequencies in the Japanese population and functional analysis. J. Pharmacol. Exp. Ther. 302, 804-813 (2002).
24. Michalski C, Cui Y, Nies AT et al.: A naturally occurring mutation in the SLC21A6 gene causing impaired membrane localization of the hepatocyte uptake transporter. J. Biol. Chem. 277, 43058-43063 (2002).
25. Kivisto KT, Niemi M: Influence of drug transporter polymorphisms on pravastatin pharmacokinetics in humans. Pharm. Res. 24, 239-247 (2007).
26. Mwinyi J, Johne A, Bauer S, Roots I, Gerloff T: Evidence for inverse effects of OATP-C (SLC21Ab) 5 and 1b haplotypes on pravastatin kinetics. Clin. Pharmacol. Ther. 75, 415-421 (2004).
27. Nishizato Y, Ieiri I, Suzuki H et al.: Polymorphisms of OATP-C ( SLC21A6) and OAT3 (SLC22A8) genes: consequences for pravastatin pharmacokinetics. Clin. Pharmacol. Ther. 73, 554-565 (2003).
28. Bruckert E, Lievre M, Giral P et al.: Short-term efficacy and safety of extended-release fluvastatin in a large cohort of elderly patients. Am. J. Geriatr. Cardiol. 12, 225-231 (2003).
29. de Kok JB, Wiegerinck ET, Giesendorf BA, Swinkels DW: Rapid genotyping of single nucleotide polymorphisms using novel minor groove binding DNA oligonucleotides (MGB probes). Hum. Mutat. 19, 554-559 (2002).
30. Ding K, Zhou K, He F, Shen Y: LDA - a java-based linkage disequilibrium analyzer. Bioinformatics 19, 2147-2148 (2003).
31. Mwinyi J, Kopke K, Schaefer M, Roots I, Gerloff T: Comparison of SLCO1B1 sequence variability among German, Turkish, and African populations. Eur. J. Clin. Pharmacol. 64(3), 257-266 (2008).
32. Maeda K, Ieiri I, Yasuda K et al.: Effects of organic anion transporting polypeptide 1B1 haplotype on pharmacokinetics of pravastatin, valsartan, and temocapril. Clin. Pharmacol Ther. 79, 427-439 (2006).
33. Niemi M, Schaeffeler E, Lang T et al.: High plasma pravastatin concentrations are associated with single nucleotide polymorphisms and haplotypes of organic anion transporting polypeptide-C (OATP-C, SLCO1B1). Pharmacogenetics 14, 429-440 (2004).
34. Pasanen MK, Neuvonen M, Neuvonen PJ, Niemi M: SLCO1B1 polymorphism markedly affects the pharmacokinetics of simvastatin acid. Pharmacogenet. Genomics 16, 873-879 (2006).
35. Niemi M, Pasanen MK, Neuvonen PJ: SLCO1B1 polymorphism and sex affect the pharmacokinetics of pravastatin but not fluvastatin. Clin. Pharmacol. Ther. 80, 356-366 (2006).
36. Mangravite LM, Krauss RM: Pharmacogenomics of statin response. Curr. Opin. Lipidol. 18, 409-414 (2007).
37. Choi JH, Lee MG, Cho JY, Lee JE, Kim KH, Park K: Influence of OATP1B1 genotype on the pharmacokinetics of rosuvastatin in Koreans. Clin. Pharmacol. Ther. 83(2), 251-257 (2007).
38. Tachibana-Iimori R, Tabara Y, Kusuhara H et al.: Effect of genetic polymorphism of OATP-C (SLCO1B1) on lipid-lowering response to HMG-CoA reductase inhibitors. Drug Metab. Pharmacokinet. 19, 375-380 (2004).
39. Thompson JF, Man M, Johnson KJ et al.: An association study of 43 SNPs in 16 candidate genes with atorvastatin response. Pharmacogenomics J. 5, 352-358 (2005).
40. Takane H, Miyata M, Burioka N et al.: Pharmacogenetic determinants of variability in lipid-lowering response to pravastatin therapy. J. Hum. Genet. 51, 822-826 (2006).
41. Igel, M, Arnold KA, Niemi M et al.: Impact of the SLCO1B1 polymorphism on the pharmacokinetics and lipid-lowering efficacy of multiple-dose pravastatin. Clin. Pharmacol. Ther. 79, 419-426 (2006).
42. Hedman M, Antikainen M, Holmberg C et al.: Pharmacokinetics and response to pravastatin in paediatric patients with familial hypercholesterolaemia and in paediatric cardiac transplant recipients in relation to polymorphisms of the SLCO1B1 and ABCB1 genes. Br. J. Clin. Pharmacol. 61, 706-715 (2006).
43. Pasanen MK, Neuvonen PJ, Niemi M: Global analysis of genetic variation in SLCO1B1. Pharmacogenomics 9, 19-33 (2008).